Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression changes induced by paclitaxel in MCF7 breast cancer cells

ABSTRACT: Time-dependent changes in gene expression induced by paclitaxel in the breast adenocarcinoma cell line MCF7. Keywords: genetic modification

ORGANISM(S): Homo sapiens

PROVIDER: GSE4298 | GEO | 2007/12/21

SECONDARY ACCESSION(S): PRJNA94679

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Gene Expression Pattern in EP300 knocked-down MCF7 cells and corresponding paclitaxel resistant derivatives

Project description:EP300, a transcriptional co-activator of E-cadherin, has been recently found by our group to regulate doxorubicin resistance via by-pass of senescence and paclitaxel resistance by overcoming apoptosis in a minimally transformed mammary epithelial cells (MTMEC). Moreover, EP300 deleted MTMEC cells exhibit an multi-drug resistant (MDR) phenotype independent of P-glycoprotein (ABCB1), an efflux pump or ABC drug transporter. This whole transcriptome array study was undertaken in order to explore the downstream targets in the EP300-mediated drug resistance, epidermal-to-mesenchymal transition and cancer stem cell phenotypes in breast cancer cell line MCF7.

2017-06-13 | GSE76200 | GEO

Breast cancer cell lines treated with eribulin and paclitaxel

Project description:Eribulin mesylate is a synthetic macrocyclic ketone analog of the marine sponge natural product halichondrin B. Eribulin is a mechanistically unique inhibitor of microtubule dynamics, leading to inhibition of microtubule growth in the absence of effects on microtubule shortening at microtubule plus ends, and formation of nonproductive tubulin aggregates. In this study, we investigated whether selective signal pathways were associated with eribulin activity compared to paclitaxel, which stabilizes microtubules, based on gene expression profiling of cell line panels of breast, endometrial, and ovarian cancer in vitro. 27 breast cancer cell lines treated with eribulin and paclitaxel for 24 hours at concentration 10xIC50. Three technical replicates were included. for eribulin , paclitaxel and untreated cell lines.

2014-10-02 | E-GEOD-50811 | biostudies-arrayexpress

Insulin stimulated MCF7 breast cancer cells

Project description:Proteome profile of MCF7 breast cancer cells stimulated with insulin and analyzed by nano-LC-ESI-MS/MS.

2016-11-30 | PXD004051 | Pride

FOXK2 geneknockown induces transcriptomic changes in breast cancer cell line MCF7

Project description:To investigate the effect of FOXK2 knockdown on transcriptomic profiling in breast cancer and delineate the role of FOXK2 in breast cancer growth. We knockdowned the gene exprssion of FOXK2 in MCF7 cells and performed gene expression profiling analysis using data obtained from RNA-seq.

2023-09-11 | GSE230623 | GEO

Effect of short-term glucose withdrawal on gene expression of MCF7 cells

Project description:MCF7 is an epithelial cell line isolated from the breast tissue of a patient with metastatic adenocarcinoma. Whether glucose autoregulates its own metabolism remains poorly understood. To probe this, we performed RNA-Seq analysis on MCF7 breast cancer cells cultured with/without short-term glucose withdrawal.

2023-06-29 | GSE206393 | GEO

Biomarker analysis of neoadjuvant Doxorubicin/Cyclophosphamide followed by Ixabepilone or Paclitaxel in early-stage breast cancer

Project description:A randomized, open-label, multicenter, phase II trial (NCT00455533) enrolled previously untreated women with histologically-confirmed primary invasive breast adenocarcinoma (T2–3, N0–3, M0, tumor size ≥2.0 cm), regardless of hormone receptor or HER2 expression status. Patients received sequential neoadjuvant therapy starting with 4 cycles of AC (doxorubicin 60 mg/m2 intravenously and cyclophosphamide 600 mg/m2 intravenously) given every 3 weeks, followed by 1:1 randomization to either ixabepilone (40 mg/m2 3-hour infusion) every 3 weeks for 4 cycles, or paclitaxel (80 mg/m2 1-hour infusion) weekly for 12 weeks. Fresh tumor biopsies at screening were a mandatory prerequisite for study entry for biomarker analyses. Gene expression profiling was performed by Affymetrix GeneChip to determine if pre-specified gene models could distinguish between the clinical activity of two microtubule stabilizing agents, ixabepilone and paclitaxel. Three core needle tumor tissue biopsies were obtained from all subjects before neoadjuvant therapy with AC and immediately combined in RNAlater® solution for subsequent RNA extraction, cRNA labeling and gene expression profiling. Pre-specified gene models were tested for their capacity to distinguish pathologic complete response rates between the AC followed by ixabepilone versus the AC followed by paclitaxel treatment regimens. All samples were collected prior to treatment. All subject received cyclophosphamide/doxorubicin (AC) prior to randomization to either Ixabepilone or Paclitaxel.

2013-01-01 | E-GEOD-41998 | biostudies-arrayexpress

A chemical screen identifies PRMT5 as a therapeutic vulnerability for paclitaxel-resistant triple-negative breast cancer

Project description:Paclitaxel -resistant triple negative breast cancer (TNBC) remains one of the most challenging breast cancers to treat. Using an epigenetic chemical probe screen, we uncover an acquired vulnerability of paclitaxel-resistant TNBC cells to protein arginine methyltransferases (PRMTs) inhibition. Analysis of cell lines and in-house clinical samples demonstrates that resistant cells evade paclitaxel killing through stabilizing mitotic chromatin assembly. Genetic or pharmacologic inhibition of PRMT5 alters RNA splicing, particularly intron retention of Aurora kinases B (AURKB), leading to a decrease in protein expression, and finally results in selective mitosis catastrophe in paclitaxel-resistant cells. These findings are fully recapitulated in a patient derived xenograft (PDX) model generated from a paclitaxel-resistant TNBC patient, providing the rationale for targeting PRMTs in paclitaxel-resistant TNBC.

2024-06-21 | GSE264630 | GEO

microRNA expression profile of MCF7 cells with retroviral inducible expression of ΔNp63α [miRNA]

Project description:MCF7 is a breast adenocarcinoma cell line which exhibits properties of differentiated luminal epithelial cells. ΔNp63α, an N-terminally truncated isoform of p51/p63 protein, plays a critical role in mammary gland development. Here, we inducibly express ΔNp63α in MCF7 cells and studied its role in stemness of breast cancer cells.

2015-12-28 | GSE64954 | GEO

Identification of ZNF217 interactors in MCF7 breast cancer cell line

Project description:Identification of TRPS1 interactors in MCF7 breast cancer cell line.

2018-07-17 | PXD010312 | Pride

mRNA expression profile of MCF7 cells with retroviral inducible expression of ΔNp63α [total RNA]

2015-12-28 | GSE64953 | GEO